Crystal engineering of pharmaceutical co-crystals from polymorphic active pharmaceutical ingredients

Chemical Communications

Volumn , Issue 36, 2005, Pages 4601-4603

  Vishweshwar, Peddy ^a   McMahon, Jennifer A ^a   Peterson, Matthew L ^b   Hickey, Magali B ^b   Shattock, Tanise R ^a   Zaworotko, Michael J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b TransForm Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBENZOIC ACID; AMIDE; CARBOXYLIC ACID; GENTISIC ACID; PIRACETAM;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG INDUSTRY; DRUG SYNTHESIS;

EID: 26444620704     PISSN: 13597345     EISSN: None     Source Type: Journal    
DOI: 10.1039/b501304f     Document Type: Article

References (63)

1. (a) G. M. J. Schmidt, Pure Appl. Chem., 1971, 27, 647;
2. (b) F. H. Allen, O. Kennard and R. Taylor, Acc. Chem. Res., 1983, 16, 146;
3. (c) G. R. Desiraju, Crystal Engineering: the Design of Organic Solids, Elsevier, Amsterdam, 1989;
4. (d) M. C. Etter, Acc. Chem. Res., 1990, 23, 120;
5. (e) C. B. Aakeröy, Acta Crystallogr., Sect. B: Struct. Sci., 1997, 53, 569.
6. J. D. Dunitz, Perspect. Supramol. Chem., 1996, 2, 1.
7. G. R. Desiraju, Angew Chem., Int. Ed. Engl., 1995, 34, 2311.
8. (a) B. Moulton and M. J. Zaworotko, Chem. Rev., 2001, 101, 1629;
9. (b) B. F. Hoskins and R. Robson, J. Am. Chem. Soc., 1990, 112, 1546;
10. (c) M. Eddaoudi, D. B. Moler, H. L. Li, B. L. Chen, T. M. Reineke, M. O'Keeffe and O. M. Yaghi, Acc. Chem. Res., 2001, 34, 319;
11. (d) S. Kitagawa, R. Kitaura and S. Noro, Angew. Chem. Int. Ed., 2004, 43, 2334;
12. (e) C. Janiak, Dalton Trans., 2003, 2781;
13. (f) S. L. James, Chem. Soc. Rev., 2003, 276.
14. M. Oh, G. B. Carpenter and D. A. Sweigart, Angew. Chem. Int. Ed., 2003, 42, 2026.
15. M. W. Hosseini, Coord. Chem. Rev., 2003, 240, 157.
16. (a) Ö. Almarsson and M. J. Zaworotko, Chem. Commun., 2004, 1889;
17. (b) R. B. Walsh, M. W. Bradner, S. Fleischman, L. A. Morales, B. Moulton, N. Rodriguez-Hornedo and M. J. Zaworotko, Chem. Commun., 2003, 186;
18. (c) S. G. Fleischman, S. S. Kuduva, J. A. McMahon, B. Moulton, R. D. B. Walsh, N. Rodriguez-Hornedo and M. J. Zaworotko, Cryst. Growth Des., 2003, 3, 909;
19. (d) J. A. McMahon, J. A. Bis, P. Vishweshwar, T. R. Shattock, O. L. McLaughlin and M. J. Zaworotko, Z. Kristallogr., 2005, 220, 340;
20. (e) J. F. Remenar, S. L. Morissette, M. L. Peterson, B. Moulton, J. M. MacPhee, H. R. Guzman and Ö. Almarsson, J. Am. Chem. Soc., 2003, 125, 8456;
21. (f) S. L. Morissette, Ö. Almarsson, M. L. Peterson, J. F. Remenar, M. J. Read, A. V. Lemmo, S. Ellis, M. J. Cima and C. R. Gardner, Adv. Drug Delivery Rev., 2004, 56, 275;
22. (g) S. L. Childs, L. J. Chyall, J. T. Dunlap, V. N. Smolenskaya, B. C. Stahly and P. G. Stahly, J. Am. Chem. Soc., 2004, 126, 13335;
23. (h) G. Bettinetti, M. R. Caira, A. Callegari, M. Merli, M. Sorrenti and C. Tadini, J. Pharm. Sci., 2000, 89, 478;
24. (i) J. A. Zerkowski, J. C. MacDonald and G. M. Whitesides, Chem. Mater., 1997, 9, 1933.
25. J. S. Buck and W. S. Ide, J. Am. Chem. Soc., 1931, 53, 2784.
26. (a) A. R. Ling and J. L. Baker, J. Chem. Soc. Trans., 1893, 63, 1314;
27. (b) J. S. Anderson, Nature, 1937, 140, 583.
28. F. H. Allen and O. Kennard, Chemical Design Automation News, 1993, 8, 31.
29. K. Huang, D. Britton, M. C. Etter and S. R. Byrn, J. Mater. Chem., 1997, 7, 713.
30. (a) K. Tanaka and F. Toda, Chem. Rev., 2000, 100, 1025;
31. (b) J. N. Gamlin, R. Jones, M. Leibovitch, B. Patrick, J. R. Scheffer and J. Trotter, Acc. Chem. Res., 1996, 29, 203;
32. (c) G. W. V. Cave, C. L. Raston and J. L. Scott, Chem. Commun., 2001, 2159;
33. (d) K. Tanaka, Solvent-free Synthesis, Wiley-VCH, Weinheim, 2003.
34. A. S. Cannon and J. C. Warner, Cryst. Growth Des., 2002, 2, 255.
35. (a) Ö. Almarsson, M. B. Hickey, M. L. Peterson, S. L. Morissette, C. McNulty, S. Soukasene, M. Tawa, M. MacPhee and J. F. Remenar, Cryst. Growth Des., 2003, 3, 927;
36. (b) S. Datta and D. J. W. Grant, Nat. Rev. Drug Discovery, 2004, 3, 42;
37. (c) I. D. H. Oswald, D. R. Allen, P. A. McGregor, W. D. S. Motherwell, S. Parsons and C. R. Pulham, Acta Crystallogr., Sect. B: Struct. Sci., 2002, 58, 1057.
38. (a) C. Giurgea, F. E. Moeyersoons and A. C. Evraerd, Arch. Int. Pharmacodyn., 1967, 166, 238;
39. (b) G. Admiraal, J. C. Eikelenboom and A. Vos, Acta Crystallogr., Sect. B: Struct. Crystallogr. Cryst. Chem., 1982, 38, 2600;
40. (c) D. Louder, M. Louder, V. A. Dzyabchenko, V. Agafonov and R. Ceolin, Acta Crystallogr., Sect. B: Struct. Sci., 1995, 51, 182;
41. (d) F. P. A. Fabbiania, D. R. Allan, S. Parsons and C. R. Pulham, CrystEngComm, 2005, 7, 179.
42. (a) E. Ginoulhiac, F. Semenza and L. Mainardi, Boll. Soc. Ital. Biol. Sper., 1950, 26, 583;
43. (b) A. Pavlova, K. Konstantinova, H. Daskalov and A. Georgiev, Pharmazie, 1983, 38, 634.
44. B. M. Kariuki, C. L. Bauer, K. D. M. Harris and S. J. Teat, Angew. Chem. Int. Ed., 2000, 39, 4485.
45. K. Scheuer, A. Rostock, R. Bartsch and W. E. Müller, Pharmacopsychiatry, 1999, 32, 10.
46. M. Kuhnert-Brandstaetter, A. Burger and R. Voellenklee, Sci. Pharm., 1994, 62, 307.
47. (a) A. Lorico, P. Masturzo, S. Villa, M. Salmona, N. Semeraro and G. De Gaetano, Biochem. Pharmacol., 1986, 35, 2443;
48. (b) M. Ohsako, C. Nakamura and O. Tsuzuki, Yakuzaigaku, 1995, 55, 261;
49. (c) J. F. Cunha, F. D. Campestrini, J. B. Calixto, A. Scremin and N. Paulino, Braz. J. Med. Biol. Res., 2001, 34, 381.
50. M. Haisa, S. Kahsino, S. I. Kanada, K. Tanaka, S. Okazaki and M. Shibagaki, Acta Crystallogr., Sect. B: Struct. Crystallogr. Cryst. Chem., 1982, 38, 1480 (CSD refcodes: BESKAL, BESKAL01).
51. (a) T. J. M. Luo and G. T. R. Palmore, Cryst. Growth Des., 2002, 2, 337;
52. (b) C. B. Aäkeroy, G. S. Bahra, C. R. Brown, P. B. Hitchcock, Y. Patell and K. R. Seddon, Acta Chem. Scand., 1995, 49, 762.
53. 2 obs = 0.108. CCDC 262605.‡ Microcrystals of 4 can also be obtained by grinding 1 and 2 in a 1:1 ratio for four minutes in a ball mill or by melting the two components.
54. (a) S. Harkema, J. W. Bats, A. M. Weyenberg and D. Feil, Acta Crystallogr., Sect B: Struct. Crystallogr. Cryst. Chem., 1972, 28, 1646;
55. (b) L. Leiserowitz and F. Nader, Acta Crystallogr., Sect B: Struct. Crystallogr. Cryst. Chem., 1977, 33, 2719.
56. 2 obs = 0.109. CCDC 262606.‡ Microcrystals of 5 can also be obtained by grinding 1 and 3 in a 1:1 ratio for four minutes in a ball mill or by melting the two components.
57. CSD refcodes: AJALAY, FURAOX, NEMTEE, RAHGEM, UNEZIW, UNEZOC, UNEZUI, UROXAM, XEWTIC and ZODWIY.
58. (a) S. L. Morissette, S. Soukasene, D. Levinson, M. J. Cima and O. Almarsson, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 2180;
59. (b) J. Bernstein, Polymorphism in Molecular Crystals, Oxford University Press, Oxford, 2002.
60. CSD refcodes: AJAJEA, EXUQUJ, HADKUT, JICTUK, MACCID, MUROXA, PDTOMS10, PTZTCQ, QUIDON, TECCAF01 and ZIGPAG.
61. (a) A. V. Trask, W. D. S. Motherwell and W. Jones, Chem. Commun., 2004, 890;
62. (b) A. V. Trask, N. Shan, W. D. S. Motherwell, W. Jones, S. Feng, R. B. H. Tan and K. J. Carpenter, Chem. Commun., 2005, 880;
63. (c) A. V. Trask, W. D. S. Motherwell and W. Jones, Cryst. Growth Des., 2005, 5, 1013.